Skip to main content

Advertisement

SpringerLink
Log in

Disorders of phosphate homeostasis in children, part 2: hypophosphatemic and hyperphosphatemic disorders

  • Review
  • Published:
Pediatric Radiology Aims and scope Submit manuscript

Abstract

Phosphorus, predominantly in the form of inorganic phosphate PO4−3, has many essential physiological functions. In the skeleton, phosphate and calcium form the mineral component and phosphate is also essential in regulating function of skeletal cells. Considerable advances have been made in our understanding of phosphate homeostasis since the recognition of fibroblast growth factor-23 (FGF23) as a bone-derived phosphaturic hormone. This second part of a two-part review of disorders of phosphate homeostasis in children covers hypophosphatemic and hyperphosphatemic disorders that are of interest to the pediatric radiologist, emphasizing, but not limited to, those related to abnormalities of FGF23 signaling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348

    Article  Google Scholar 

  2. Levine BS, Kleeman CR, Felsenfeld AJ (2009) The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport. Clin J Am Soc Nephrol 4:1866–1877

    Article  CAS  PubMed  Google Scholar 

  3. Christov M, Jüppner H (2018) Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab 32:685–706

    Article  CAS  PubMed  Google Scholar 

  4. Koumakis E, Cormier C, Roux C et al (2020) The causes of hypo- and hyperphosphatemia in humans. Calcif Tissue Int 108:41–73

    Article  PubMed  Google Scholar 

  5. Michigami T, Ozono K (2019) Roles of phosphate in skeleton. Front Endocrinol 10:180

    Article  Google Scholar 

  6. Razali NN, Hwu TT, Thilakavathy K (2015) Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets. J Pediatr Endocrinol Metab 28:1009–1017

    Article  CAS  PubMed  Google Scholar 

  7. Bitzan M, Goodyer PR (2019) Hypophosphatemic rickets. Pediatr Clin N Am 66:179–207

    Article  Google Scholar 

  8. Lambert AS, Linglart A (2018) Hypocalcaemic and hypophosphatemic rickets. Best Pract Res Clin Endocrinol Metab 32:455–476

    Article  CAS  PubMed  Google Scholar 

  9. Whyte MP, Schranck FW, Armamento-Villareal R (1996) X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 81:4075–4080

    CAS  PubMed  Google Scholar 

  10. Liu S, Guo R, Simpson LG et al (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426

    Article  CAS  PubMed  Google Scholar 

  11. Imel EA (2020) Congenital conditions of hypophosphatemia in children. Calcif Tissue Int 108:74–90

    Article  PubMed  PubMed Central  Google Scholar 

  12. Carpenter TO, Imel EA, Holm IA et al (2011) A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381–1388

    Article  PubMed  Google Scholar 

  13. Gohil A, Imel EA (2019) FGF23 and associated disorders of phosphate wasting. Pediatr Endocrinol Rev 17:17–34

    PubMed  PubMed Central  Google Scholar 

  14. Bacchetta J, Bardet C, Prié D (2020) Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. Metabolism 103s:153865

    Article  PubMed  Google Scholar 

  15. Beck-Nielsen SS, Brixen K, Gram J et al (2013) High bone mineral apparent density in children with X-linked hypophosphatemia. Osteoporos Int 24:2215–2221

    Article  CAS  PubMed  Google Scholar 

  16. Oliveri MB, Cassinelli H, Bergadá C et al (1991) Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemic rickets (XLH). Bone Miner 12:91–100

    Article  CAS  PubMed  Google Scholar 

  17. Reid IR, Murphy WA, Hardy DC et al (1991) X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. Am J Med 90:63–69

    Article  CAS  PubMed  Google Scholar 

  18. Shore RM, Langman CB, Poznanski AK (2000) Lumbar and radial bone mineral density in children and adolescents with X-linked hypophosphatemia: evaluation with dual X-ray absorptiometry. Skelet Radiol 29:90–93

    Article  CAS  Google Scholar 

  19. Rauch F (2006) Material matters: a mechanostat-based perspective on bone development in osteogenesis imperfecta and hypophosphatemic rickets. J Musculoskelet Neuronal Interact 6:142–146

    CAS  PubMed  Google Scholar 

  20. Frost HM (1987) The mechanostat: a proposed pathogentic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents. Bone Miner 2:73–85

    CAS  PubMed  Google Scholar 

  21. Arango Sancho P (2020) Complications of phosphate and vitamin D treatment in X-linked hypophosphataemia. Adv Ther 37:105–112

    Article  CAS  PubMed  Google Scholar 

  22. Colares Neto GP, Ide Yamauchi F, Hueb Baroni R et al (2019) Nephrocalcinosis and nephrolithiasis in X-linked hypophosphatemic rickets: diagnostic imaging and risk factors. J Endocr Soc 3:1053–1061

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Carpenter TO, Imel EA, Ruppe MD et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124:1587–1597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Carpenter TO, Whyte MP, Imel EA et al (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987–1998

    Article  CAS  PubMed  Google Scholar 

  25. Imel EA, Glorieux FH, Whyte MP et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416–2427

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Insogna KL, Briot K, Imel EA et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383–1393

    Article  CAS  PubMed  Google Scholar 

  27. Santos Rodriguez F (2020) X-linked hypophosphataemic rickets and growth. Adv Ther 37:55–61

    Article  CAS  PubMed  Google Scholar 

  28. Whyte MP, Carpenter TO, Gottesman GS et al (2019) Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189–199

    Article  PubMed  Google Scholar 

  29. Athonvarangkul D, Insogna KL (2021) New therapies for hypophosphatemia-related to FGF23 excess. Calcif Tissue Int 108:143–157

    Article  CAS  PubMed  Google Scholar 

  30. Fukumoto S (2021) FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol 66:R57–R65

    Article  CAS  PubMed  Google Scholar 

  31. Harada D, Ueyama K, Oriyama K et al (2021) Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets. J Pediatr Endocrinol Metab 34:791–798

    Article  CAS  PubMed  Google Scholar 

  32. Imel EA (2021) Burosumab for pediatric X-linked hypophosphatemia. Curr Osteoporos Rep 19:271–277

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bacchetta J, Rothenbuhler A, Gueorguieva I et al (2021) X-linked hypophosphatemia and burosumab: practical clinical points from the French experience. Joint Bone Spine 88:105208

    Article  CAS  PubMed  Google Scholar 

  34. Ferreira CR, Kintzinger K, Hackbarth ME et al (2021) Ectopic calcification and hypophosphatemic rickets: natural history of ENPP1 and ABCC6 deficiencies. J Bone Miner Res 36:2193–2202

    Article  CAS  PubMed  Google Scholar 

  35. Ferreira CR, Hackbarth ME, Ziegler SG et al (2021) Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet Med 23:396–407

    Article  CAS  PubMed  Google Scholar 

  36. Höppner J, Kornak U, Sinningen K et al (2021) Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) due to ENPP1-deficiency. Bone 153:116111

    Article  PubMed  Google Scholar 

  37. Stern R, Levi DS, Gales B et al (2021) Correspondence on "prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al. Genet Med 23:2006–2007

    Article  PubMed  Google Scholar 

  38. Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18:R53–R77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Drezner MK (2001) Tumor-induced osteomalacia. Rev Endocr Metab Disord 2:175–186

    Article  CAS  PubMed  Google Scholar 

  40. Farrow EG, White KE (2009) Tumor-induced osteomalacia. Expert Rev Endocrinol Metab 4:435–442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Florenzano P, Hartley IR, Jimenez M et al (2020) Tumor-induced osteomalacia. Calcif Tissue Int 108:128–142

    Article  PubMed  Google Scholar 

  42. Yin Z, Du J, Yu F, Xia W (2018) Tumor-induced osteomalacia. Osteoporos Sarcopenia 4:119–127

    Article  PubMed  PubMed Central  Google Scholar 

  43. Harrison HE (1973) Oncogenous rickets: possible elaboration by a tumor of a humoral substance inhibiting tubular reabsorption of phosphate. Pediatrics 52:432–434

    Article  CAS  PubMed  Google Scholar 

  44. Jan De Beur SM, Finnegan RB, Vassiliadis J et al (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102–1110

    Article  CAS  Google Scholar 

  45. Shimada T, Mizutani S, Muto T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500–6505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Folpe AL, Fanburg-Smith JC, Billings SD et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30

    Article  PubMed  Google Scholar 

  47. Jiang Y, Xia WB, Xing XP et al (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27:1967–1975

    Article  PubMed  Google Scholar 

  48. Chande S, Bergwitz C (2018) Role of phosphate sensing in bone and mineral metabolism. Nat Rev Endocrinol 14:637–655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lee JC, Su SY, Changou CA et al (2016) Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29:1335–1346

    Article  CAS  PubMed  Google Scholar 

  50. Minisola S, Peacock M, Fukumoto S et al (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044

    Article  PubMed  Google Scholar 

  51. Jung GH, Kim JD, Cho Y et al (2010) A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatr Orthop B 19:127–132

    Article  PubMed  Google Scholar 

  52. Fernández-Cooke E, Cruz-Rojo J, Gallego C et al (2015) Tumor-induced rickets in a child with a central giant cell granuloma: a case report. Pediatrics 135:e1518–e1523

    Article  PubMed  Google Scholar 

  53. Crossen SS, Zambrano E, Newman B et al (2017) Tumor-induced osteomalacia in a 3-year-old with unresectable central giant cell lesions. J Pediatr Hematol Oncol 39:e21–e24

    Article  PubMed  Google Scholar 

  54. Ma GM, Chow JS, Taylor GA (2019) Review of paraneoplastic syndromes in children. Pediatr Radiol 49:534–550

    Article  PubMed  Google Scholar 

  55. Duet M, Kerkeni S, Sfar R et al (2008) Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med 33:752–756

    Article  PubMed  Google Scholar 

  56. Jan de Beur SM, Streeten EA, Civelek AC et al (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359:761–763

    Article  CAS  PubMed  Google Scholar 

  57. Nguyen BD, Wang EA (1999) Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 24:130–131

    Article  CAS  PubMed  Google Scholar 

  58. El-Maouche D, Sadowski SM, Papadakis GZ et al (2016) 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 101:3575–3581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia. Bone Rep 7:90–97

    Article  PubMed  PubMed Central  Google Scholar 

  60. Rayamajhi SJ, Yeh R, Wong T et al (2019) Tumor-induced osteomalacia — current imaging modalities and a systematic approach for tumor localization. Clin Imaging 56:114–123

    Article  PubMed  Google Scholar 

  61. Andreopoulou P, Dumitrescu CE, Kelly MH et al (2011) Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26:1295–1302

    Article  PubMed  Google Scholar 

  62. Hesse E, Rosenthal H, Bastian L (2007) Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 357:422–424

    Article  CAS  PubMed  Google Scholar 

  63. de Castro LF, Ovejero D, Boyce AM (2020) Diagnosis of endocrine disease: mosaic disorders of FGF23 excess: fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome. Eur J Endocrinol 182:R83–R99

    Article  PubMed  PubMed Central  Google Scholar 

  64. Riminucci M, Collins MT, Fedarko NS et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Collins MT, Singer FR, Eugster E (2012) McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 7:S4

    Article  PubMed  PubMed Central  Google Scholar 

  66. Kuznetsov SA, Cherman N, Riminucci M et al (2008) Age-dependent demise of GNAS-mutated skeletal stem cells and "normalization" of fibrous dysplasia of bone. J Bone Miner Res 23:1731–1740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Bhattacharyya N, Wiench M, Dumitrescu C et al (2012) Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 27:1132–1141

    Article  CAS  PubMed  Google Scholar 

  68. Aschinberg LC, Solomon LM, Zeis PM et al (1977) Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 91:56–60

    Article  CAS  PubMed  Google Scholar 

  69. Lim YH, Ovejero D, Sugarman JS et al (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23:397–407

    Article  CAS  PubMed  Google Scholar 

  70. Ovejero D, Lim YH, Boyce AM et al (2016) Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos Int 27:3615–3626

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Heike CL, Cunningham ML, Steiner RD et al (2005) Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis? Am J Med Genet 139A:67–77

    Article  CAS  PubMed  Google Scholar 

  72. Pitt MJ (2002) Rickets and osteomalacia. In: Resnick D (ed) Diagnosis of bone and joint disorders, 4th edn. Saunders, Philadelphia, pp 1901–1946

    Google Scholar 

  73. White KE, Cabral JM, Davis SI et al (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361–367

    Article  CAS  PubMed  Google Scholar 

  74. Wagner CA, Rubio-Aliaga I, Hernando N (2017) Renal phosphate handling and inherited disorders of phosphate reabsorption: an update. Pediatr Nephrol 34:549–559

    Article  PubMed  Google Scholar 

  75. Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401

    Article  PubMed  Google Scholar 

  76. Ito N, Fukumoto S (2021) Congenital hyperphosphatemic conditions caused by the deficient activity of FGF23. Calcif Tissue Int 108:104–115

    Article  CAS  PubMed  Google Scholar 

  77. Roberts MS, Burbelo PD, Egli-Spichtig D et al (2018) Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. J Clin Invest 128:5368–5373

    Article  PubMed  PubMed Central  Google Scholar 

  78. Resnick D (2002) Soft tissue disorders. In: Resnick D (ed) Diagnosis of bone and joint disorders, 4th edn. W. B. Saunders, Philadelphia, pp 4635–4695

    Google Scholar 

  79. Martinez S, Vogler JB 3rd, Harrelson JM, Lyles KW (1990) Imaging of tumoral calcinosis: new observations. Radiology 174:215–222

    Article  CAS  PubMed  Google Scholar 

  80. Olsen KM, Chew FS (2006) Tumoral calcinosis: pearls, polemics, and alternative possibilities. Radiographics 26:871–885

    Article  PubMed  Google Scholar 

  81. Boyce AM, Lee AE, Roszko KL, Gafni RI (2020) Hyperphosphatemic tumoral calcinosis: pathogenesis, clinical presentation, and challenges in management. Front Endocrinol 11:293

    Article  Google Scholar 

  82. Ramnitz MS, Gourh P, Goldbach-Mansky R et al (2016) Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome. J Bone Miner Res 31:1845–1854

    Article  CAS  PubMed  Google Scholar 

  83. Folsom LJ, Imel EA (2015) Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action. Curr Osteoporos Rep 13:78–87

    Article  PubMed  Google Scholar 

  84. Clarke E, Swischuk LE, Hayden CK Jr (1984) Tumoral calcinosis, diaphysitis, and hyperphosphatemia. Radiology 151:643–646

    Article  CAS  PubMed  Google Scholar 

  85. Talab YA, Mallouh A (1988) Hyperostosis with hyperphosphatemia: a case report and review of the literature. J Pediatr Orthop 8:338–341

    Article  CAS  PubMed  Google Scholar 

  86. Narchi H (1997) Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics 99:745–748

    Article  CAS  PubMed  Google Scholar 

  87. Frishberg Y, Ito N, Rinat C et al (2007) Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22:235–242

    Article  CAS  PubMed  Google Scholar 

  88. Slavin RE, Wen J, Barmada A (2012) Tumoral calcinosis — a pathogenetic overview: a histological and ultrastructural study with a report of two new cases, one in infancy. Int J Surg Pathol 20:462–473

    Article  PubMed  Google Scholar 

  89. Finer G, Price HE, Shore RM et al (2014) Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. Am J Med Genet A 164A:1545–1549

    Article  PubMed  Google Scholar 

  90. Ito E, Konno Y, Toki T, Terui K (2010) Molecular pathogenesis in diamond-Blackfan anemia. Int J Hematol 92:413–418

    Article  CAS  PubMed  Google Scholar 

  91. Vervloet MG (2020) FGF23 measurement in chronic kidney disease: what is it really reflecting? Clin Chim Acta 505:160–166

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

I would like to thank Aaron L. Friedman, MD, for his helpful advice.

Author information

Authors and Affiliations

  1. Department of Medical Imaging, Ann & Robert H. Lurie Children’s Hospital of Chicago, 225 E. Chicago Ave., Chicago, IL, 60611, USA

    Richard M. Shore

  2. Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Richard M. Shore

Authors
  1. Richard M. Shore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard M. Shore.

Ethics declarations

Conflicts of interest

None

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shore, R.M. Disorders of phosphate homeostasis in children, part 2: hypophosphatemic and hyperphosphatemic disorders. Pediatr Radiol 52, 2290–2305 (2022). https://doi.org/10.1007/s00247-022-05373-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00247-022-05373-z

Keywords

Search

Navigation